L-glucose, a mirror isomer of D-glucose, is usually considered unusable by living organisms. However, in 2010, we discovered that malignant tumor cells specifically take up L-glucose (patented internationally). We have since worked with physicians and researchers to develop cancer-targeting drugs and diagnostics using L-glucose. Our goal is to bring a cure to patients with intractable cancers.
Simply hold the mid-infrared laser to your hand to measure blood sugar levels in just 5 seconds. This startup offers safe and convenient blood glucose monitoring that eliminates the need for blood sampling, reducing physical and mental burden while minimizing infection risks and medical waste.
Leveraging world-leading autophagy measurement technology, we provide end-to-end solutions from material evaluation and supplement/cosmetic development to drug discovery research. A startup demonstrating results in international competitions, aiming for the societal implementation of extended healthy lifespans.
Elcyo develops innovative autofocal glasses that automatically adjust focus with proprietary lens technology. Leveraging Fresnel Liquid Crystal Lens Technology, Elcyo has made it possible to create glasses that maintain focus at any distance, addressing a wide range of vision challenges across healthcare, entertainment, and beyond.
A Kyoto-based startup has developed the world's first cell therapy enabling nerve regeneration using ES/iPS cell-derived Schwann cells. This breakthrough enables large-scale production of cells previously difficult to mass-produce, paving the way for clinical trials.
